Palamur Biosciences

What Palamur Biosciences does

Palamur Biosciences Private Limited is an India-based preclinical contract research organization (CRO) founded in 2008, headquartered in Secunderabad with its primary GLP test facility in Mahabubnagar, Telangana. The company operates as a full-service preclinical research provider spanning rodents to large animals — including beagle dogs, mini pigs, sheep, goats, and non-human primates (Rhesus and Cynomolgus macaques) — and serves the pharmaceutical, biotechnology, agrochemical, and medical device industries with GLP-compliant toxicology, safety pharmacology, pharmacokinetics, and efficacy studies. Its service portfolio is organized into five core lines (Pharma-Biotech, Agrochemical, Medical Devices/MRIDA, Research and Innovation, Laboratory Animal Models) plus standalone services such as GLP-certified pathology and specialized platforms including cardiovascular telemetry with surgically implanted devices, imaging-enabled canine PK studies, and NHP-based CAR-T and gene therapy evaluation. MRIDA, the medical device testing division focused on cardiology and interventional devices, was established with government support under NBM and BIRAC.

The business model is professional-services fee-for-service B2B contract research, with pricing negotiated per study based on species, complexity, and regulatory requirements; revenue is not publicly disclosed. The company maintains international sales and operations offices in Columbia, Maryland (United States) and China to access North American and East Asian sponsor markets, with a sales-led go-to-market motion executed through direct business development outreach, industry conferences, and a corporate website. Leadership includes Dr. S Ramamoorthy (CEO), Mr. Deepu Menon (Director of Business Development), and Dr. T. Kumar (Director of Operations), and the firm holds an unusually deep stack of regulatory accreditations — OECD GLP, AAALAC, NABL ISO/IEC 17025, US FDA 21 CFR Part 58, DSIR, CPCSEA, CIBRC, SENASA, and OLAW (2025) — positioning it to produce data acceptable to US FDA, US EPA and other leading regulatory agencies. The firm is privately held with 51-100 employees, no disclosed institutional investors or funding rounds, and no parent company.

Name

Palamur Biosciences

Legal name

Palamur Biosciences Private Limited

Website

https://palamurbio.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

51–100 employees

Short description

Palamur Biosciences is an India-based preclinical CRO founded in 2008 that provides GLP-compliant toxicology, safety pharmacology, pharmacokinetics, and efficacy studies across rodents to large animals for pharmaceutical, biotech, agrochemical, and medical device sponsors globally.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industries

Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), In Vivo Pharmacology (Efficacy/PD Models) (HLAGAFAA)

Keywords

• Preclinical CRO services
• GLP toxicology studies
• Safety pharmacology testing
• Non-human primate research
• Medical device testing

Headquarters

HQ city

Secunderabad

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Contract Research Services: Preclinical contract research organization providing fee-for-service GLP toxicology studies, safety pharmacology, pharmacokinetics, and efficacy studies for pharmaceutical, biotech, agrochemical, and medical device companies. Revenue generated through contract study fees based on study complexity, duration, and animal species required.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Palamur Biosciences is a full-service preclinical Contract Research Organization (CRO) that delivers GLP-compliant toxicology, safety pharmacology, pharmacokinetic, and efficacy studies on a fee-for-service basis. It operates an integrated facility housing animal models ranging from rodents to non-human primates (beagle dogs, mini pigs, sheep, Rhesus and Cynomolgus monkeys) and provides dedicated medical device testing under its MRIDA division for pharmaceutical, biotechnology, agrochemical, and medical device sponsors globally.

Product overview

Palamur Biosciences is a full-service preclinical Contract Research Organization (CRO) established in 2008, offering an integrated portfolio of GLP-compliant research services. The core offerings include Pharma-Biotech (drug discovery and regulatory services), Agrochemical testing, Medical Devices (MRIDA), Research and Innovation, and Laboratory Animal Research Models. Supporting these core areas are specialized services such as Pathology Services (clinical pathology and histopathology), Cardiovascular Telemetry Studies, Imaging-Enabled Canine PK Studies, and NHP Research with CAR-T Cell Therapy Platform. The organization operates species ranging from rodents to large animals including beagle dogs, NHPs, swine, goats, and sheep, serving agrochemical, pharma, R&D, biotech, and medical device segments.

Differentiator

Problem solved

Functional benefit

Brands

• MRIDA: Medical devices testing and training division, established under the aegis of NBM and BIRAC. Dedicated Medical Devices testing facility for Cardiology and Interventional Medical Devices.

Products and services

• Pharma-Biotech Preclinical CRO Services Drug discovery and regulatory services with GLP-compliant preclinical testing for pharmaceutical and biotechnology compounds, drawing on a pool of scientists with extensive experience in drug discovery and regulatory services.
• Agrochemical GLP Testing Services GLP-compliant facility managed by experienced personnel delivering regulatory toxicology and safety assessment studies for agrochemical and pesticide products, including CIBRC-registered studies for Indian submissions.
• MRIDA Medical Devices Testing and Training Dedicated medical devices testing and training division for cardiology and interventional medical devices, including biocompatibility, stent histology, resin-embedded tissue processing, and regulatory support for device sponsors.
• Research and Innovation Services Pool of scientists with extensive research experience undertaking exploratory studies and basic research across multiple therapeutic areas, complementing the regulated GLP service portfolio.
• Laboratory Animal Research Models Supply Specialized laboratory animal breeding providing research models including beagles, mice, guinea pigs, minipigs, and large animals for preclinical studies, operating under CPCSEA/CCSEA-approved breeding, trading, and testing facility status.
• Standalone Services Extended support offerings including GLP-certified clinical and anatomical pathology services (hematology, clinical chemistry, coagulation, electrolytes, urine, blood gas, gross and histopathology, special staining, immunohistochemistry, and image analysis) for discovery and regulatory submission phases.
• Cardiovascular Telemetry Studies in Beagle Dogs Specialized cardiovascular safety pharmacology offering using surgically implanted telemetry systems in beagle dogs to deliver high-resolution, continuous physiological data for IND/NDA-enabling regulatory submissions.
• Imaging-Enabled Canine PK Studies Preclinical pharmacokinetic studies in canine models utilizing advanced fluoroscopy and gastroscopy imaging for precise verification of dosing, catheter placement, and longitudinal assessment of oral bioavailability.
• NHP Research and CAR-T / Gene Therapy Evaluation Platform Non-human primate (NHP) research facility supporting pharmacokinetic assessments, vaccine efficacy trials, gene therapy evaluation, and CAR-T cell therapy efficacy and safety evaluation using Rhesus and Cynomolgus monkey models with conventional, neuro-targeted, and specialized dosing techniques.

Quantifiable outcome

• 25+ GLP telemetry studies successfully completed with data submitted to US FDA and other leading regulatory agencies

Named customers4 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• BIRAC (Biotechnology Industry Research Assistance Council)supportingOthersMRIDA (Medical Devices testing division) was established under the aegis of NBM and BIRAC, indicating government support and funding for medical device testing infrastructure development.

Scale indicators3 records

Recent moves6 records

Expansion highlights3 records

Direct peers

• Sai Life Sciences: India-based full-service CRO offering preclinical and clinical research services to global pharma and biotech. Comparable to Palamur as a domestically rooted CRO leveraging India's cost arbitrage for outsourced drug development.
• Aragen Life Sciences (formerly GVK Biosciences): India-headquartered CRO providing preclinical, discovery, and development services. Direct competitor in the Indian preclinical outsourcing market with overlapping GLP toxicology and DMPK offerings.
• Anthem Biosciences: Bengaluru-based CRO/CDMO offering preclinical toxicology, DMPK, and discovery services. Comparable India-based competitor competing for the same GLP toxicology and safety pharmacology workload.
• Suven Life Sciences: India-based CRO/CDMO providing drug discovery, preclinical, and formulation development services. Comparable as an Indian preclinical research peer with overlapping CRO service lines.
• Toxikon: US-based preclinical CRO specializing in GLP toxicology, medical device testing, and safety assessment. Comparable as a focused preclinical CRO with overlapping toxicology and device testing capabilities.

Broad incumbents

• Syngene International: Largest listed Indian CRO offering integrated discovery, preclinical, and clinical research services with global biopharma clients. A broader incumbent in the same Indian preclinical outsourcing category.
• Charles River Laboratories: Global leader in preclinical CRO services including safety assessment, DMPK, and research models. Comparable as the dominant global incumbent in the same preclinical services categories Palamur competes in.
• WuXi AppTec: China-based global CRO/CDMO offering preclinical toxicology, safety pharmacology, and integrated drug development. Comparable as a large-scale Asian preclinical CRO competing for similar outsourcing demand.
• Labcorp Drug Development (Covance): Global CRO offering preclinical safety, DMPK, and clinical research services. Broad incumbent competing in the same preclinical CRO categories for large pharma and biotech sponsors.
• Pharmaron: China/UK-headquartered CRO offering preclinical, DMPK, safety pharmacology, and integrated drug development services. Comparable Asian-headquartered preclinical CRO with similar global sponsor base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/palamurb
• Facebookfacebook.com/PalamurBiosciences

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Palamur Biosciences